This renewal application seeks support to continue research at the Los Angeles Addiction Treatment Research Center. The proposal contains a core and four research components centered on the theme of improving opiate and cocaine pharmacotherapy. The research will be conducted within a consortium of facilities affiliated in varying degrees to UCLA and having overlapping scientific and administrative leadership provided by senior investigators of the LAATRC. The core provides scientific leadership and administrative support, centralized development of research methodology and standardized research procedures for data collection, management, analysis, interpretation and dissemination. An executive committee made up of senior investigators and led by the PI, is aided by an external scientific advisory committee of national prominence. The first component furthers buprenorphine development by testing a three-times-a-week dosing regimen, and explores strategies for buprenorphine discontinuation. Results will provide critical information for buprenorphine's NDA submission. A second component establishes a cost-effective, efficient strategy to evaluate a series of cocaine pharmacotherapy by embedding well-designed controlled clinical trials, with a dose-ranging feature, in a continuous, articulated program which employs standardized study procedures, phases in one medication after another, uses """"""""slots"""""""" from early dropouts for subjects in the next study, and reduces down time between trials. Component three will enhance the clinical utility of LAAM by examining take-home doses as a treatment strategy and exploring the use of LAAM in medically compromised addicts. A fourth component examines the relationship of opiate maintenance to pain tolerance and analgesic response to develop better clinical strategies for management of pain associated with acute medical illnesses in opiate maintained patients. The proposed work by the LAATRC will provide critical data for medication development, produce useful information for patient management, provide an enriched environment for training of scientists, and establish the center as a regional and national research resource.
| Miotto, Karen; Hillhouse, Maureen; Donovick, Roger et al. (2012) Comparison of buprenorphine treatment for opioid dependence in 3 settings. J Addict Med 6:68-76 |
| Ling, Walter; Cunningham-Rathner, Jerry; Rawson, Richard (2004) Diffusion of substance abuse treatment: will buprenorphine be a success? J Psychoactive Drugs Suppl 2:115-7 |
| Ling, Walter; Wesson, Donald R (2003) Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend 70:S49-57 |
| Lopatko, Olga V; White, Jason M; Huber, Alice et al. (2003) Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine. Drug Alcohol Depend 69:317-22 |
| Ling, Walter; Rawson, Richard A; Compton, Margaret (2003) Clinical treatment of opioid addiction and dependence. Methods Mol Med 84:285-95 |
| Doverty, M; White, J M; Somogyi, A A et al. (2001) Hyperalgesic responses in methadone maintenance patients. Pain 90:91-6 |
| Doverty, M; Somogyi, A A; White, J M et al. (2001) Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain 93:155-63 |
| Kirkish, P; Sreenivasan, S; Welsh, R et al. (2000) The future of criminal violence: juveniles tried as adults. J Am Acad Psychiatry Law 28:38-46 |
| Ling, W; Shoptaw, S; Majewska, D (1998) Baclofen as a cocaine anti-craving medication: a preliminary clinical study. Neuropsychopharmacology 18:403-4 |
| Frosch, D L; Shoptaw, S; Jarvik, M E et al. (1998) Interest in smoking cessation among methadone maintained outpatients. J Addict Dis 17:9-19 |
Showing the most recent 10 out of 12 publications
